C Bilir1, S Durak2, B Kızılkaya2, I Hacıbekiroglu3, E Nayır4, H Engin1. 1. Department of Medical Oncology, Faculty of Medicine, Sakarya University, Sakarya. 2. Department of Internal Medicine, Faculty of Medicine, Recep Tayyip Erdogan University, Rize. 3. Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne. 4. Department of Medical Oncology, Necip Fazıl City Hospital, Kahramanmaras; and.
Abstract
BACKGROUND: Metronomic chemotherapy-administration of low-dose chemotherapy-allows for a prolonged treatment duration and minimizes toxicity for unfit patients diagnosed with advanced non-small-cell lung cancer (nsclc). METHODS: Oral metronomic vinorelbine at 30 mg thrice weekly was given to 35 chemotherapy-naïve patients who were elderly and vulnerable to toxicity and who had been diagnosed with advanced nsclc. RESULTS: Median age in this male-predominant cohort (29:6) was 76 years (range: 65-86 years). Histology was squamous cell carcinoma in 21 patients and adenocarcinoma in 14. There were no complete responses and 9 partial responses, for an overall response rate of 26%. Stable disease was seen in 15 patients (43%), and 11 patients (31%) had progressive disease. The 1-year survival rate was 34%, and the 2-year survival rate was 8%. The survival analysis showed a median progression-free survival duration of 4 months (range: 2-15 months) and an overall survival duration of 7 months (range: 3-24 months). CONCLUSIONS: Metronomic vinorelbine had an acceptable efficacy and safety profile in elderly patients with multiple comorbidities who had been diagnosed with advanced nsclc. Metronomic vinorelbine could be a treatment option for elderly patients with poor performance status who are unfit for platinum-based chemotherapy and intravenous single-agent chemotherapy, and who are not candidates for combination modalities.
BACKGROUND: Metronomic chemotherapy-administration of low-dose chemotherapy-allows for a prolonged treatment duration and minimizes toxicity for unfit patients diagnosed with advanced non-small-cell lung cancer (nsclc). METHODS: Oral metronomic vinorelbine at 30 mg thrice weekly was given to 35 chemotherapy-naïve patients who were elderly and vulnerable to toxicity and who had been diagnosed with advanced nsclc. RESULTS: Median age in this male-predominant cohort (29:6) was 76 years (range: 65-86 years). Histology was squamous cell carcinoma in 21 patients and adenocarcinoma in 14. There were no complete responses and 9 partial responses, for an overall response rate of 26%. Stable disease was seen in 15 patients (43%), and 11 patients (31%) had progressive disease. The 1-year survival rate was 34%, and the 2-year survival rate was 8%. The survival analysis showed a median progression-free survival duration of 4 months (range: 2-15 months) and an overall survival duration of 7 months (range: 3-24 months). CONCLUSIONS: Metronomic vinorelbine had an acceptable efficacy and safety profile in elderly patients with multiple comorbidities who had been diagnosed with advanced nsclc. Metronomic vinorelbine could be a treatment option for elderly patients with poor performance status who are unfit for platinum-based chemotherapy and intravenous single-agent chemotherapy, and who are not candidates for combination modalities.
Entities:
Keywords:
Metronomic vinorelbine; non-small-cell lung cancer; poor performance status
Authors: M De Lena; R Ramlau; O Hansen; V Lorusso; L Wagner; S Barni; M M Cristovao; R Huber; V Alberola; M Mitrovic; C Colin; J Gasmi Journal: Lung Cancer Date: 2004-12-21 Impact factor: 5.705
Authors: J Jassem; R Ramlau; H Karnicka-Młodkowska; K Krawczyk; M Krzakowski; P Zatloukal; E Lemarié; W Hartmann; L Novakova; M O'Brien; A Depierr Journal: Ann Oncol Date: 2001-10 Impact factor: 32.976
Authors: E H Tan; J Rolski; T Grodzki; C P Schneider; U Gatzemeier; P Zatloukal; E Aitini; G Carteni; H Riska; Y H Tsai; R Abratt Journal: Ann Oncol Date: 2009-03-10 Impact factor: 32.976
Authors: A Camerini; C Valsuani; F Mazzoni; O Siclari; C Puccetti; S Donati; M Rondini; G Tartarelli; P Puccinelli; F Di Costanzo; D Amoroso Journal: Ann Oncol Date: 2009-11-13 Impact factor: 32.976
Authors: Felice Pasini; Carmen Barile; Donatella Caruso; Yasmina Modena; Anna Paola Fraccon; Laura Bertolaso; Daniela Menon; Francesca La Russa; Giorgio Crepaldi; Antonio Bononi; Roberto Spezzano; Roberto Padrini; Giuseppe Corona; Milena Gusella Journal: Invest New Drugs Date: 2018-06-28 Impact factor: 3.850
Authors: A Camerini; G L Banna; S Cinieri; A Pezzuto; M Mencoboni; F Rosetti; A Figueiredo; P Rizzo; A Ricci; L Langenhoven; A Santo; A Addeo; D Amoroso; F Barata Journal: Clin Transl Oncol Date: 2018-11-17 Impact factor: 3.405
Authors: Vittorio Gebbia; Marco Maria Aiello; Giuseppe Banna; Giusi Blanco; Livio Blasi; Nicolò Borsellino; Dario Giuffrida; Mario Lo Mauro; Gianfranco Mancuso; Dario Piazza; Giuseppina Savio; Hector Soto Parra; Maria Rosaria Valerio; Francesco Verderame; Paolo Vigneri Journal: Ecancermedicalscience Date: 2020-09-29
Authors: David Rossi; Paolo Lippe; Marco Bruno Luigi Rocchi; Donatella Sarti; Vincenzo Catalano; Francesco Graziano; Paolo Giordani; Annamaria Baldelli; Stefano Luzi Fedeli; Luca Imperatori; Gianluca Laici; Claudia Cappelletti; Tiziana Tamburrano; Raffaella Bracci; Paolo Alessandroni Journal: In Vivo Date: 2020 Sep-Oct Impact factor: 2.155